AUTHOR=Yanagimachi Masakatsu , Kato Koji , Iguchi Akihiro , Sasaki Koji , Kiyotani Chikako , Koh Katsuyoshi , Koike Takashi , Sano Hideki , Shigemura Tomonari , Muramatsu Hideki , Okada Keiko , Inoue Masami , Tabuchi Ken , Nishimura Toyoki , Mizukami Tomoyuki , Nunoi Hiroyuki , Imai Kohsuke , Kobayashi Masao , Morio Tomohiro TITLE=Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan JOURNAL=Frontiers in Immunology VOLUME=11 YEAR=2020 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01617 DOI=10.3389/fimmu.2020.01617 ISSN=1664-3224 ABSTRACT=
Hematopoietic cell transplantation (HCT) is established as a curative treatment for severe chronic granulomatous disease (CGD). However, outcomes of HCT for CGD in Japan had not been precisely reported. We evaluated the outcome of HCT for CGD in Japan by means of a nationwide survey. A total of 91 patients (86 males and 5 females) with CGD who received HCT between 1992 and 2013 was investigated. Their median age at HCT was 11 years (0–39). Sixty-four patients had X-linked CGD caused by CYBB gene mutations, 13 had autosomal recessive CGD (7 CYBA and 6 NCF2), and 14 were genetically undetermined. Seventy patients are still alive at a median follow-up of 38.9 (3.7–230) months. Three-year OS and EFS was 73.7 and 67.6%, respectively. Twenty-one patients died mainly from transplant-related mortality. The cumulative incidence of grade II to IV acute GVHD and extensive chronic GVHD was 27.2 and 17.9%, respectively. Risk factors for EFS after HCT for CGD were age >30 years (